Related Experiment Video
Updated: Mar 22, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
28.0K
Obiltoxaximab: First Global Approval.
1Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. dru@adis.com.
Drugs
|April 18, 2016
Summary
Obiltoxaximab is a new monoclonal antibody approved for preventing and treating inhalational anthrax. It works by neutralizing anthrax toxins, offering a vital medical countermeasure against Bacillus anthracis infection.
Area of Science:
- Biotechnology
- Immunology
- Infectious Diseases
Background:
- Inhalational anthrax, caused by Bacillus anthracis, poses a significant bioterrorism threat.
- Existing treatments may have limitations, necessitating novel therapeutic strategies.
Purpose of the Study:
- To summarize the development milestones of obiltoxaximab.
- To highlight its approval for inhalational anthrax prevention and treatment.
Main Methods:
- Development of obiltoxaximab, a monoclonal antibody targeting protective antigen.
- Evaluation of intravenous and intramuscular formulations.
- Regulatory approval based on the US FDA Animal Rule (animal efficacy and human safety studies).
Main Results:
- Obiltoxaximab demonstrated efficacy in relevant animal models.
- Phase I studies in healthy volunteers confirmed safety.
- Intravenous obiltoxaximab received US FDA approval in March 2016.
Conclusions:
- Obiltoxaximab represents a significant advancement in the medical countermeasures available for inhalational anthrax.
- The drug offers a dual benefit for both prophylaxis and treatment of anthrax infections.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
348
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
348
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
725
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
725
01:26FDA Approved Drugs: Changes to Approved Drugs
319
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
319
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
657
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
657
01:13Bioequivalence studies: Biowaivers
380
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
380
01:19Pharmacovigilance
1.9K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.9K